文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

R&D Department, Laboratoires de Thérapeutique Moderne, Suresnes, France.

Gen Pharmacol. 1990;21(6):821-5. doi: 10.1016/0306-3623(90)90439-s.

The evidence reviewed here indicates that pinaverium bromide (Dicetel) relaxes gastrointestinal (GI) structures primarily by inhibiting Ca2+ influx through potential-dependent channels of surface membranes of smooth muscle cells. 2. The in vivo selectivity of pinaverium bromide for the GI tract appears to be due mainly to its pharmacokinetic properties. Because of its low absorption (typical for quaternary ammonium compounds) and marked hepatobiliary excretion, most of the orally-administered dose of pinaverium bromide remains in the GI tract. 3. Orally-administered pinaverium bromide does not elicit adverse cardiovascular side-effects at doses that effectively relieve GI spasm, pain, transit disturbances and other symptoms related to motility disorders. 4. Pinaverium bromide is the only Ca2(+)-antagonist with known therapeutic efficacy in the treatment of irritable bowel syndrome and certain other functional intestinal disorders.

此处回顾的证据表明，匹维溴铵（得舒特）主要通过抑制钙离子经平滑肌细胞表面膜电压依赖性通道内流，从而松弛胃肠道（GI）结构。2. 匹维溴铵对胃肠道的体内选择性似乎主要归因于其药代动力学特性。由于其吸收较低（季铵化合物的典型特征）且有显著的肝胆排泄，口服给药的匹维溴铵大部分剂量仍留在胃肠道内。3. 口服匹维溴铵在有效缓解胃肠道痉挛、疼痛、转运紊乱及其他与动力障碍相关症状的剂量下，不会引发不良心血管副作用。4. 匹维溴铵是唯一已知对治疗肠易激综合征和某些其他功能性肠道疾病有治疗效果的钙离子拮抗剂。

R&D Department, Laboratoires de Thérapeutique Moderne, Suresnes, France.

Gen Pharmacol. 1990;21(6):821-5. doi: 10.1016/0306-3623(90)90439-s.

The evidence reviewed here indicates that pinaverium bromide (Dicetel) relaxes gastrointestinal (GI) structures primarily by inhibiting Ca2+ influx through potential-dependent channels of surface membranes of smooth muscle cells. 2. The in vivo selectivity of pinaverium bromide for the GI tract appears to be due mainly to its pharmacokinetic properties. Because of its low absorption (typical for quaternary ammonium compounds) and marked hepatobiliary excretion, most of the orally-administered dose of pinaverium bromide remains in the GI tract. 3. Orally-administered pinaverium bromide does not elicit adverse cardiovascular side-effects at doses that effectively relieve GI spasm, pain, transit disturbances and other symptoms related to motility disorders. 4. Pinaverium bromide is the only Ca2(+)-antagonist with known therapeutic efficacy in the treatment of irritable bowel syndrome and certain other functional intestinal disorders.

此处回顾的证据表明，匹维溴铵（得舒特）主要通过抑制钙离子经平滑肌细胞表面膜电压依赖性通道内流，从而松弛胃肠道（GI）结构。2. 匹维溴铵对胃肠道的体内选择性似乎主要归因于其药代动力学特性。由于其吸收较低（季铵化合物的典型特征）且有显著的肝胆排泄，口服给药的匹维溴铵大部分剂量仍留在胃肠道内。3. 口服匹维溴铵在有效缓解胃肠道痉挛、疼痛、转运紊乱及其他与动力障碍相关症状的剂量下，不会引发不良心血管副作用。4. 匹维溴铵是唯一已知对治疗肠易激综合征和某些其他功能性肠道疾病有治疗效果的钙离子拮抗剂。